Bayer eyes wider Nubeqa use on new prostate cancer trial data
Send a link to a friend
[July 17, 2024]
By Ludwig Burger
FRANKFURT (Reuters) -Bayer said on Wednesday its Nubeqa drug was shown
to slow the progression of a certain type of prostate cancer in a
late-stage trial, underpinning growth prospects for one of the German
drugmaker's key pharmaceutical products.
Bayer is developing Nubeqa, also known as darolutamide, jointly with
Finland's Orion. The drug is already approved in other prostate cancer
treatment settings.
Bayer said in a statement that Nubeqa, when combined with androgen
deprivation therapy, significantly prolonged progression-free survival
when compared with androgen deprivation therapy alone in a phase III
trail.
Trial participants suffered from a type of metastatic prostate cancer
that responds to hormone therapy.
Details of the trial would be presented at an as yet undisclosed medical
conference, Bayer said, adding that it plans to seek regulatory approval
for wider use of the drug.
[to top of second column]
|
![](../images/071724PIX/health9.jpg)
The 120-metre-high Bayer Cross, logo of German pharmaceutical and
chemical maker Bayer AG, consisting of 1710 LED glass bulbs is seen
outside the industrial park "Chempark" of the chemical industry in
Leverkusen, Germany, September 23, 2023. REUTERS/Wolfgang Rattay/File
Photo
![](http://archives.lincolndailynews.com/2024/Jul/17/images/ads/current/peasley_lda_LIGHTLOGOGENERIC_070824.png)
(Reporting by Ludwig Burger, Editing by Rachel More)
[© 2024 Thomson Reuters. All rights reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |